Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2025European Journal of Drug Metabolism and PharmacokineticsOpen Access

Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Remimazolam

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDerek E. MurrellSHSam Harirforoosh

Discussion

Loading...

Member takes

Overview

Clinical analysis reveals remimazolam's efficacy and safety in procedural sedation, suggesting lower risks compared to standard benzodiazepines.

Key Points

  • Remimazolam demonstrates non-inferiority to midazolam and propofol in sedation efficacy.
  • Randomized controlled trials indicate higher procedural success rates and faster recovery times with remimazolam.
  • Pharmacokinetic studies show a short terminal half-life of approximately 37–53 minutes, enhancing its suitability for tailored sedation.
  • Minimal impact from age or mild hepatic impairment suggests versatility across diverse patient populations.

Cite This Study

Murrell et al. (2025) studied this question.

synapsesocial.com/papers/68d46cd731b076d99fa69629https://doi.org/10.1007/s13318-025-00963-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical applications and pharmacological characteristics of remimazolam, a short-acting sedative: a narrative review2026 · 2 citations
  2. 2Remimazolam: Bridging safety, stability, and recovery in contemporary anesthesia2026
  3. 3Remimazolam in anesthesia and sedation: A narrative review2025 · 1 citations
  4. 4Pharmacological profiles and mechanism of action of remimazolam for ICU sedation2026 · 5 citations
  5. 5Remimazolam and its place in the current landscape of procedural sedation and general anesthesia2024